TScan Therapeutics, Inc. TCRX
0.34
(0.01)
(2.86%)
as of 25 Sep
- Market cap
- $23.7M
- P/E
- 0.0×
Follow TCRX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (95.80%) | (80.95%) | (71.28%) | (76.44%) |
+8 more TTM periods Free account |
|
| (50.09%) | (46.50%) | (43.26%) | (46.73%) | ||
ROIC |
(4,588.23%) | (5,295.51%) | (2,610.99%) | 0.00% | |
Return on Tangible Assets |
(145.00%) | (102.80%) | (88.14%) | (84.75%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.91) | (0.96) | (1.08) | (1.05) | |
Free Cash Flow |
(118.41) | (124.96) | (139.73) | (135.85) | |
Capital Expenditures |
(2.13) | (2.94) | (4.41) | (5.12) | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(57.58%) | (47.36%) | (43.93%) | (36.22%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,364.56% | 1,163.16% | 1,105.57% | 1,465.81% | |
Selling, General and Administrative Expense of Revenue |
430.59% | 345.58% | 309.81% | 399.20% | |
Share Based Compensation of Revenue |
138.39% | 117.74% | 113.38% | 147.36% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.98 | 1.04 | 0.92 | |
Depreciation/Fixed assets |
0.37 | 0.35 | 0.33 | 0.31 | |
Capex/Depreciation |
(0.74) | (1.02) | (1.54) | (1.80) | |
Revenue per Share |
0.05 | 0.07 | 0.08 | 0.06 | |
Operating CF per Share |
(0.89) | (0.94) | (1.04) | (1.01) | |
Capex per Share |
(0.02) | (0.02) | (0.03) | (0.04) | |
Capex to Sales |
0.30 | 0.32 | 0.43 | 0.61 | |
Net Profit Margin |
(1,655.35%) | (1,360.61%) | (1,256.81%) | (1,692.96%) |
Columns are period end dates